

#3 1-16-91

07-24(688)A



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

THOMAS F. DEUEL,  
YUE-SHENG LI,  
NED R. SIEGEL AND  
PETER G. MILNER

GROUP ART UNIT: 186 ✓

SERIAL NUMBER: 07/542,232

EXAMINER:

FILED: JUNE 21, 1990

TITLE: HEPARIN-BINDING GROWTH FACTOR

SUPPLEMENTAL

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR 1.97-1.99

Hon. Commissioner of Patents and Trademarks  
Washington, D. C. 20231


RECEIVED  
DEC 13 1990  
PAT. & TRADEMARK OFF.

Dear Sir:

This is a supplement to the Information Disclosure Statement filed July 23, 1990 in the above-identified application. On December 11, 1990, the undersigned received a copy of European Patent Application 326,075, published August 2, 1989, but which he was not aware of previously. A copy of said application (identified herewith as document E), together with Form 1449, is enclosed for the convenience of the Examiner.

The relevance of document E is that it discloses a heparin-binding brain mitogen (HBBM) in which the disclosed 19 amino acids of the N-terminus are the same as the first 19 amino acids of the heparin-binding growth factor (HBGF-8) claimed herein. However, applicant's growth factor (HBGF-8) is derived from bovine uterus or human placenta whereas the protein (HBBM) described in document E is derived from brain tissues. Moreover, applicant's HBGF-8 is characterized by a complete amino acid sequence of 168 residues which is not disclosed in document E. In view of its brain tissue origin, the protein of document E appears to be the same as the heparin-binding protein of document D rather than applicant's novel HBGF-8.

Respectfully submitted,

  
\_\_\_\_\_  
Scott J. Meyer  
Attorney for Applicants  
Registration No. 25,275

Monsanto Company  
800 N. Lindbergh Blvd.  
Mail Zone - A3SD  
St. Louis, Missouri 63167  
(314) 694-3117

December 11, 1990